Clinical Trials Logo

Clinical Trial Summary

A prospective study of three different doses of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF


Clinical Trial Description

A prospective study of three different doses of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF:Single dose of Degarelix 24mg, 16mg and 12 mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.

ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.

On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.

On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.

On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03240159
Study type Interventional
Source Assisting Nature
Contact Evaggelos Papanikolaou, MD, PhD
Phone 00302310424294
Email drvagpapanikolaou@yahoo.gr
Status Recruiting
Phase Phase 3
Start date February 15, 2017
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03463278 - The Number of Blastocysts Formed in the Outcome of Freeze All Strategy: COMFFETI Trial, Cumulative Delivery Rate
Completed NCT02442895 - Biomarkers of Ovarian Reserve and Correlation With IVF Treatments N/A
Completed NCT00773825 - Genomic Imprinting and Assisted Reproductive Technologies N/A
Recruiting NCT03693534 - Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol
Recruiting NCT03684421 - Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Classical Antagonist Protocol